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Small interfering RNA silences specific genes by interfering with mRNA translation, and acts
to modulate or inhibit specific biological pathways; a therapy that holds great promise in
the cure of many diseases. However, the naked small interfering RNA is susceptible to
degradation by plasma and tissue nucleases and due to its negative charge unable to cross
the cell membrane. Here we report a new polymer carrier designed to mimic the influenza
virus escape mechanism from the endosome, followed by a timed release of the small
interfering RNA in the cytosol through a self-catalyzed polymer degradation process.
Our polymer changes to a negatively charged and non-toxic polymer after the release of
small interfering RNA, presenting potential for multiple repeat doses and long-term treatment
of diseases.
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S
mall interfering RNA (siRNA) silences specific genes by
interfering with mRNA translation, and therefore acts to
modulate or inhibit specific biological pathways1–3. The
siRNA-based therapy holds great promise in the cure of cancers
and many other diseases. However, the naked siRNA is
susceptible to degradation by plasma and tissue nucleases and
is unable to cross the cell membrane due to its negative charge.
This has necessitated the design of delivery vehicles to overcome
the inherent siRNA cell transport barriers. Amongst many
investigated approaches, the initial work with viral delivery
carriers showed great promise for delivering DNA and other
biomolecules4,5. Viruses have evolved with exquisite strategies to
deliver their payload efficiently within a cell; for example, the
enveloped influenza virus easily appropriates the cellular
machinery to replicate itself6. This virus first becomes
endocytosed, and utilizes this transportation process to reach
the inner parts of the cell. Before reaching the lysosome, the acidic
pH triggers a rapid geometric conformational change of the
haemagglutinin (HA) protein, releasing the HA2 membrane
fusion peptide that binds and facilitates fusion of the virus with
the endosome membrane. The virus escapes into the cytosol
where it then proceeds to replicate its genome7. However, despite
the above advantages, viral delivery devices have associated safety
concerns due to non-specific interruption of genes and induction
of an immune response4,5.
Development of non-viral siRNA delivery systems incorporat-
ing the strategies of the virus could provide a safer, cheaper and
effective treatment for various diseases8,9. Among synthetic
delivery vehicles, cationic polymers and lyposomes are widely
known as nanocarriers for siRNA; they bind via electrostatic
interactions to form complexes with the siRNA that are rapidly
taken up by cells10,11. The polymer carriers usually incorporate a
pH buffering molecule that acts as a ‘proton sponge’ or binds to
the endosome membrane to facilitate their escape12,13. Although
such systems have demonstrated utility in nonhuman primate
studies for liver-related diseases due to the natural accumulation
of the carrier in the liver14–17, the permanent cationic charge of
the nanocarriers18,19 makes release of the siRNA difficult20–22.
The accumulation of cationic species could result in unwanted
toxicity especially when administered in multiple doses. To
overcome the release problem of siRNA, polymers have been
designed to incorporate side chain molecules that trigger a release
when stimulated using temperature23, pH24, redox potential25,26,
light27, electrical pulse28,29 and enzymatic degradation30,31. Such
release mechanisms rely on either external (remote) or environ-
mental stimuli. The complication arises in that many tissues and
organs are not remotely accessible, and environmentally triggered
stimuli can vary between cell lines and even within the same
tissue or organ. Furthermore, after degradation, the polymers
should form biologically benign particles avoiding toxic buildup
in the tissues32,33.
In the work reported here, we overcame these delivery
challenges by designing our polymer carrier to deliver siRNA
using some of the strategies inspired by viruses. The polymer
carrier consists of a diblock copolymer with a first block
of poly(2-dimethylaminoethyl acrylate) (PDMAEA, pKaB7.1).
The PDMAEA block is cationic at physiological pH and degrades
into the negatively charged and non-toxic poly(acrylic acid)
(PAA) (Fig. 1a) in water through a self-catalyzed hydrolysis
mechanism32. The degradation time to form PAA is independent
of pH (as tested between pH 5.5 and 10.1) and the molecular
weight of PDMAEA. This block segment can therefore bind
strongly to siRNA and release it at a defined time (that is, ‘timed
release’) independent of the physiological pH, allowing the
delivery of siRNA into tissues not accessible through external or
environmental triggers. The resulting negatively charged polymer
should be relatively benign after release even after multiple doses.
A second block consisting of P(N-(3-(1H-imidazol-1-yl)propyl)
acrylamide (PImPAA) and poly(butyl acrylate) (PBA)18 was
designed to induce fusion with the endosome membrane (and act
in a similar way to the fusion peptide HA2) that results in escape
of the polymer/siRNA complex to the cytosol where release of the
siRNA can occur after degradation to PAA (see Fig. 1a). In this
work, we designed a range of block copolymers (Fig. 1b) to
examine the mode of delivery and release using an osteosarcoma
cell line as a proven siRNA model system, and determine cell
death through siRNA knockdown of the polo-like kinase 1
(PLK1) pathway. The best polymer carrier from this study was
then trialed in vitro to silence the MAPK–ERK1/2 pathway in
primary chondrocytes.
Results
Synthesis and physiochemical properties of polymers. Single
electron transfer-living radical polymerization (SET-LRP)34,35 of
DMAEA produced PDMAEA (polymer A in Supplementary
Methods and Supplementary Table S1 in Supporting
Information) with a number-average molecular weight (Mn) of
4,200 and a polydispersity index (PDI) of 1.29 determined by size
exclusion chromatography based on polystyrene standards
and neglecting differences in polymer hydrodynamic volume
(see Supplementary Figs S1–S3). A more accurate value of 9,430
determined by 1H NMR showed that the polymer consisted of 65
DMAEA units. This polymer was previously tested as a delivery
vehicle for siRNA, showing 490% cell uptake after 4 h and low
cytotoxicity32,33, and thus was used as the first block in this work.
PDMAEA65 was extended with blocks containing units of
ImPAA, BA and/or dimethylacrylamide (DMA) comonomers as
shown in Fig. 1b using the SET-LRP technique. Conversion of
monomer to polymer was kept low (o40%) to avoid high levels
of radical–radical termination and further maintain a high -Cl
chain-end functionality to produce block copolymers (A–B1 to
A–D3) with PDIs below 1.3 (Supplementary Table S1).
The number of repeating units for all comonomers was given
in Fig. 1b and Supplementary Table S1 based on 1H NMR
analysis (see Supplementary Figs S4–S7).
Complexation of an oligo DNA (23 bp) with the A–B polymer
series in water showed an increase in size (i.e. diameter, Dh) from
B5 to 200 nm with an increase in the N/P ratio (i.e. nitrogen to
phosphorus ratio) from 0 to 10 (see Supplementary Table S2).
A similar trend was found for the A–C and A–D series, but here
the initial Dh (at N/P¼ 0) showed that the incorporation of the
hydrophobic monomers, BA and ImPAA, in the second block
gave small polymeric micelles ofB15 to 20 nm (A–C1 to A–C3).
The A–C3 polymer candidate showed that at an N/P ratio of 10 at
pH 7.6, these small 20 nm nanoparticles aggregated with the oligo
DNA to result into a narrow particle size distribution close to
200 nm in size as shown in Fig. 1c. Leaving the complex of A–C3/
oligo DNA in water at pH 7.6 resulted in its degradation after
17 h, whereby the size decreased from 200 to 20 nm and the oligo
DNA was fully released (see the Agarose gel in Fig. 1c). A similar
profile was found when the complex was kept at pH 5.5, with full
release of the oligo DNA after 25 h and a size decrease to 5 nm
(Fig. 1c) corresponding to the size of an individual polymer
coil (i.e. unimer) in solution. This result suggests that the siRNA
(with a similar size to the oligo DNA) can still be complexed with
the polymer in the low pH environment of the endosome, and if
escape from the endosome is faster than the release time of
B17 h, the siRNA has a great chance of being released within the
cytosol. The similar degradation profiles of A–C3 in pH 5.5 and
7.6 further supported a non-triggered and timed-release
mechanism of the siRNA from the polymer carrier. In addition,
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the degradation profiles for A–B3 and A–D3 at pH 7.6 and 5.5
were all similar to A–C3, suggesting that only the degradation of
PDMAEA to PAA plays the dominant role for release of oligo
DNA (see Supplementary Figs S9–S14).
In vitro RNAi-mediated knockdown of PLK1 in osteosarcoma.
Osteosarcoma is a bone cancer prevalent in young people, with
poor survival rates. Polo-like kinase 1 (PLK1) has an important
role in maintaining tumorgenic phenotype of osteosarcoma
cells36. Its knockdown using siRNA delivery should induce
selective growth arrest and cell death. In this work, we used the
U-2OS cell line as an in vitro model system to test our polymers
(from Fig. 1b) for knockdown using a previously screened
siRNA36. We evaluated the knockdown of U-2OS cells using our
polymer-loaded siRNA complexes via a cell viability assay. Four
siRNAs were used: (i) siRNA targeting PLK1, (ii) universal
negative control (Mission siRNA, Sigma-Aldrich), (iii) scrambled
siRNA for PLK, and (iv) a negative control S10 siRNA that targets
another pathway37. The polymer-loaded siRNA complexes were
also compared with oligofectamine/siRNA complexes, in which
oligofectamine is regarded as the gold standard for siRNA
delivery. Solutions of the polymer and siRNA in PBS buffer at
various N/P ratios (that is, 0 to 10) were mixed and incubated for
30min at room temperature. The complex was then added to
the cells in complete DMEM media at 37 C, and after 4 h, the
cells were washed to remove any complex not taken up by the
cells and incubated for another 48 h. The concentration of siRNA
used in this assay was 50 nM.
It can be seen that polymer A loaded with siRNA by itself
(that is, PDMAEA65) showed little toxicity and little or no
knockdown compared with oligofectamine-loaded siRNA
targeting PLK1 (see Supplementary Fig S15A). Incorporating an
ImPAA second block (A–B series) to act as either a proton
sponge or fusogenic polymer also showed little toxicity and little
or no cell death irrespective of the molecular weight of the second
block when loaded with PLK1 siRNA(Fig. 2a and Supplementary
Fig. S15B–D). The results suggest that even with the inclusion of
ImPAA (similar functional group to histidine), the polymer
carrier could not escape the endosome. Polymer series
A–C incorporating not only ImPAA but hydropobic BA was
synthesized to further assist in endosome escape. The cell viability
data (Fig. 2b and Supplementary Fig. S16) using A–C2 and A–C3
loaded with PLK1 siRNA showed little or no cell death at N/P
ratios below 10. At an N/P ratio of 10, both polymers loaded with
PLK1 siRNA complexes showed excellent knockdown (480%)
and little toxicity. This amount of cell viability loss specific
to targeting the PLK1 pathway was substantially better than
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Figure 1 | Polymer structure and assembly. (a) Mechanism for polymer assembly, binding with siRNA and release of siRNA through a
self-catalyzed degradation of PDMAEA, (b) chemical structures of the nine block copolymers, and (c) degradation profile of polymer A–C3 at
pH 7.6 and 5.5 when complexes with oligo DNA as measured by DLS, and the time for release of the oligo DNA from the polymer carrier.
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oligofectamine/siRNA. To test whether cell death was due to the
combination of ImPAA and BA in the second block or as a result
of only BA, we synthesized the A–D polymer series consisting of
BA and DMA in the second block. The results for A–D3 (Fig. 2c)
and A–D1 and A–D2 (Supplementary Fig. S17) showed
that without ImPAA there was no observed cell death. The
combination of ImPAA and BA in the second block demonstrates
that both comonomers act synergistically to allow escape of the
polymer/siRNA complex from the endosome into the cytosol,
most probably due to the combined ionic and hydrophobic
interactions with the endosome membrane. To confirm that cell
death was primarily due to siRNA targeting PLK, we tested two
different control siRNAs (universal negative control (denoted as
Uni) and a scrambled siRNA (denoted as Scr)) delivered with
polymer A–C3, and the data given in Fig. 2d shows that there is
no knockdown with either of these siRNAs. Further, the cell
viability of polymer A–C3 alone before (Supplementary Fig.
S19A) and after (Supplementary Fig. S19B) degradation (that is,
self-catalyze to poly(acrylic acid)) of the PDMAEA block in A–C3
showed little or no cell toxicity even at an NP ratio of 20. These
results collectively demonstrate the excellent knockdown
potential of A–C3 with little or no cytotoxicity.
Escape from the endosome is thus a key feature of our polymer
carrier that allows effective delivery of the siRNA to the cytosol.
Two mechanisms have been proposed for pH-responsive
polymers (for example, with imidazole groups) to facilitate
escape12,13: (i) an osmotic gradient caused by a flux of counter
ions to maintain the ionic strength in the endosome and thus
induce endosome lysis, or (ii) interaction of the imidazole groups
with the endosome membrane. Our results showed that the
siRNA targeting PLK gave B80% knockdown with little or no
toxicity from the polymer A–C3. The requirement for the
combination of ImPAA and BA in the second block (A–C series)
demonstrates the capability of these monomer units to fuse
with the endosome membrane and facilitate escape. The ImPAA
(that is, imidazole) side groups become highly protonated when
the pH drops below its pKa of B6, which should enable these
positive charges to interact with the negatively charged endosome
membrane and induce a bilayer phase separation. The BA
monomer units should further interact with the membrane
through hydrophobic interactions and facilitate fusion with the
membrane leading to escape. As described earlier, the fusogenic
second block in A–C2 and A–C3 is located in the core of the
micelle with a size of B20 nm (Supplementary Table S2),
and must therefore be exposed to the surface of the micelles
when the pH drops in the endosome to interact with the
endosome membrane, mimicking structural reorganization found
for the influenza virus. When the polymer without siRNA was
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Figure 2 | In vitro knockdown efficiencies. U-2OS cell in vitro knockdown efficiency of (a) P(DMAEA65-b-ImPAA43) (A–B3), (b) P(DMAEA65-b-
(ImPAA45-co-BA29)) (A–C3), and (c) P(DMAEA65-b-(DMA45-co-BA35)) (A–D3) complexes with siRNA targeting PLK and negative siRNA control S10 at
N/P ratios of 1, 5 and 10 after 30min complexation in water. The polymers were added to the cells and left to transfect for 4 h, and further incubated for
48 h. Controls used were untreated (Control), PLK/Oligofectamine complex (Oligofect–PLK), S10/Oligofectamine (Oligofect–S10) complexes, PLK siRNA
only (PLK only) and S10 siRNA only (S10 only). Concentrations of PLK and S10 used was 50 nM. The data are reported as the mean±s.e.m. of three
replicates. (d) U-2OS cell viability of P(DMAEA)65-P(ImPAA45-co-BA29) (A–C3) complexes with universal siRNA (Uni) and scrambled siRNA (Scr)
at N/P ratio 1, 5 and 10 after 30min complexation in water, 4 h transfection and 48 h incubation. Controls used are untreated (Control). Concentration
of universal siRNA and scrambled siRNA used is 50 nM. The data are reported as the mean±standard error of the mean of two replicates. Values in
parenthesis are N/P ratios.
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self-assembled in water at pH 7.6, small micelles formed with a
size of B20 nm (Supplementary Table S3). When the pH was
decreased to 5.5, the polymer was fully water soluble and the
polymer chains dissociated from the micelle forming unimers of
B5 nm. Increasing the pH back to 7.6 resulted in reconstitution
(self-assembly) of the unimers back to small B20 nm particles.
The polymer (A–C3)/oligo DNA complex showed no change in
particle size when the pH was decreased from 7.6 to 5.5 (Fig. 1).
These results suggested that the 20 nm polymer particles when
complex with the siRNA formed a large 200 nm aggregate, and
when in the endosome, the size of the aggregate did not change
due to the strong ionic binding between the siRNA and polymer
chains even though the ImPAA groups were now cationic and
hydrophilic. Our observations are consistent with the fully water
soluble ImPAA and BA second block reorganizing in the
endosome to be exposed to the exterior of the aggregate,
allowing fusion and escape from the endosome membrane.
Once in the cytosol, release of the siRNA occurs after 17 h, which
acts to interfere with the specific mRNA.
In vitro RNAi-mediated knockdown of ERK in osteoarthritis
chrondrocytes. The MAPK–ERK (mitogen activated protein
kinase-extracellular signal-regulated kinase) cell signaling path-
way has been identified as one of the central regulatory factors in
osteoarthritis (OA) progression, especially in the altered com-
munication between the osteoarthritic cartilage and the
subchondral bone38. We evaluated the efficiency of the polymer
A–C3 loaded with siRNA targeting ERK in OA chondrocytes.
Articular cartilage cells (ACCs) were isolated from OA cartilage,
and the early passage cells (P1-2) were used in the in vitro
experiments. The polymer/siRNA concentrations used in this
study showed no significant cytotoxic effects in siRNA treatment
groups using the standard LDH (lactate dehydrogenase) assay
(Fig. 3a). The A–C3 polymer loaded with ERK siRNA diminished
ERK1/2 (ERK1/2) levels in severe OA ACCs measured using the
western blot analysis after 48 h (Fig. 3b). This in vitro knockdown
of ERK enhanced chondrocyte differentiation and impaired
pathological phenotytic changes in severe OA ACCs (Fig. 3c).
The polymer A–C3 alone was not toxic to the OA ACCs even at
an NP ratio of 20 before (Supplementary Fig. S20A) and after
(Supplementary Fig. S20B) degradation of the PDMAEA part of
the polymer. Knockdown by siRNA specific to the ERK pathway
was further demonstrated using a universal negative siRNA
control and a scrambled siRNA, both of which showed no
knockdown capability (Supplementary Fig. S21). ACCs from
severe OA knee cartilage (Mankin score Z6) showed a poor
capacity for chondrogenic differentiation with higher levels of
hypertrophic and degenerative markers. When A–C3-loaded ERK
siRNA was delivered to the severe OA ACCs, the degradative
enzymes of ADAMTS5 (disintegrin and metalloproteinase with
thrombospondin motifs 5), MMP-13 (matrix metalloproteinases
13) and pathological hypertrophic markers of type 10 collagen
(COL10) and Runt-related transcription factor-2 (RUNX2) were
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significantly decreased. In contrast, we observed increased levels
of chondrogenic markers COL2 and AGAN (Fig. 3c). These
findings collectively indicated that ERK siRNA loaded into our
polymer (A–C3) improved the chondrogenic differentiation and
inhibited the pathological degradative and hypertrophic changes
in OA ACCs.
Discussion
We demonstrate the use of a sophisticated polymer delivery
carrier for the delivery of siRNA to silence distinct pathways. Our
polymer was designed where one block binds electrostatically
with siRNA and then degrades to a negatively charged side
groups that repels and releases the siRNA. It takes 17 h in pH 7.6
to release the siRNA. This is more than sufficient time for the
polymer carrier/siRNA to escape the endosome and release the
siRNA in the cytosol. The second block consisting of ImPAA and
BA resulted in a polymer carrier mimicking the escape
mechanism of the influenza virus from the endosome into the
cytosol. A distinct advantage of our polymer is that it forms a
non-toxic negatively charged polymer, allowing the potential
for multiple doses and effective treatment of the disease.
Our polymer carrier was effective in siRNA knockdown with
480% of cell death when targeting the PLK1 pathway for
osteosarcoma cancer cells, and when targeting the ERK1/2
pathway shown to be the key regulatory pathway in OA. These
results demonstrate great promise for the application of our
A–C3 polymer as an effective and safe siRNA delivery carrier for
further applications in many diseases.
Methods
Synthesis and characterization of polymers. Details of the syntheses
including materials used, and complete polymer characterization by size
exclusion chromatography, 1H nuclear magnetic resonance and dynamic light
scattering and provided in the Supplementary Methods section, along with
details of the agarose gel assays for binding and release studies.
Osteocarcoma model assays. Details of the osteocarcoma model assays,
including in-vitro studies of knockdown of osteosarcoma U-2OS cells and
examination of cell viability of osteosarcoma U-2OS cells using Cell Titer-Glo
assay are provided in the Supplementary Methods section.
Osteoarthritis model assays. Details of the osteoarthritis model assays,
including in-vitro cytotoxicity studies and examination of cell viability of
osteosarcoma OA ACCs cells using Cell Titer-Glo assay are provided in the
Supplementary Methods section.
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